Fushilai Pharmaceutical Ingredients (APIs) and Intermediates CM/CDMO Construction Project

• Project Overview

This project is invested and constructed by Suzhou Fushilai Pharmaceutical Co., Ltd. As the second main-board listed company introduced to Yicheng Chemical Industry Park after Borui Pharmaceutical, following the park’s approval as a provincial-level industrial park, the company is headquartered in Changshu, Suzhou. It was founded in 2000 and listed on the Shenzhen Stock Exchange in 2022, achieving a consolidated operating income of 568.2 million yuan in the same year.The company holds an absolute advantage in its niche segments: the direct export volume of its lipoic acid series products accounts for 37.6% of the national total export volume of such products, ranking second in the industry; the direct export volumes of both its phosphorylcholine series and carnosine series products rank first in the industry.

• Customer background and challenges

This project plans to invest 500 million yuan, covering an area of 220 mu (about 14.67 hectares), and will construct 48,000 square meters of various workshops and office facilities, as well as build 15 new production lines for active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It will produce featured APIs and pharmaceutical intermediates such as rimegepant sulfate (used for the treatment of diabetic neuropathy and neurological complications), mirogabalin besylate (used for peripheral neuropathic pain), and finerenone (used for diabetic-related chronic kidney disease). These products are sold far to overseas markets including Europe, America, Japan, South Korea, India and South America.Meanwhile, the company has established strategic cooperation partnerships with leading pharmaceutical enterprises such as Rixin Pharmaceutical USA and Hengrui Medicine. It will successively deploy multiple projects in our district, including fermentation-based drugs, preparations, and small nucleic acid drugs, laying a solid foundation for further expanding the pharmaceutical market.

• Our Solutions

This project was recommended for bidding participation by Shandong New Times Pharmaceutical Co., Ltd., a subsidiary of Lunan Pharmaceutical Group. The design work was undertaken by China National Pharmaceutical Group Chongqing Pharmaceutical Design Institute Co., Ltd.Upon learning of the project information at the very beginning, Huarong Company promptly formulated a targeted plan. It developed the scheme by coordinating three parties: the promoter, the design institute and the project owner, and ultimately won the bid for the project. The specific measures are as follows:

1. The Promoter:Mr. Kong from Shandong New Times Pharmaceutical recommended our brand for the shortlist to the project owner. Shandong New Times Pharmaceutical has maintained cooperation with us since 2018 and we have signed an annual cooperation framework agreement covering all explosion-proof area products including explosion-proof electrical appliances, lamps, and pipe fittings. This framework agreement has been continuously extended to date, which fully demonstrates Shandong New Times Pharmaceutical’s high recognition of Huarong’s products and services.

2. The Designer：This project is designed by China National Pharmaceutical Group Chongqing Pharmaceutical Design Institute Co., Ltd. Our company has long maintained liaison with Chongqing Pharmaceutical Design Institute and has built a familiar rapport with every designer on its team.：The bidding for this project mainly covers the raw material workshop, four Class A warehouses, the tank farm, and the outdoor rainwater and sewage pump control cabinets, with explosion-proof distribution boxes as the core products. Upon getting wind of the project information, we took the initiative to contact the design institute to clarify the technical requirements for the bidding, and coordinated with the designers to set up technical thresholds—for example, establishing criteria related to product certifications and structural specifications—and formulated technical scoring items that are favorable to our bid.
3. The Project Owner：Although this is the first time we have engaged with the project owner—Fushilai (Shandong) Pharmaceutical Co., Ltd.—our track record of numerous projects in the Shandong market is well recognized. Qilu Pharmaceutical, Lunan Pharmaceutical, Shandong NHU Pharmaceutical, Shandong Puluo Pharmaceutical and many others are our long-term partners with signed annual cooperation framework agreements, and they are all leading enterprises in their respective pharmaceutical segments.Therefore, when we presented our company scale, product quality, and technical services to the project owner, we gained its full recognition.

• Implementation Process &Timeline

This project was launched in December 2023. The bidding for explosion-proof equipment kicked off in June 2025, and Huarong won the bid eventually. Huarong supplies goods to the site in batches in accordance with the project schedule, and coordinates with the project construction progress throughout the process to ensure the timely delivery of materials.

• Results & Data Highlights

Shandong is a major province both in the chemical industry and the pharmaceutical industry. Qilu Pharmaceutical operates 12 factories across Shandong. Many leading pharmaceutical enterprises such as Lunan Pharmaceutical and its subsidiary Shandong New Times Pharmaceutical have invested and set up plants in Shandong, leaving enormous potential for market expansion.Through the successful experience of this project, we have gained an in-depth understanding of the operation process of pharmaceutical and chemical projects. By coordinating multiple parties and seizing the overall initiative, we successfully secured the project.

• Customer Feedback

During the project execution, the regional manager and technical person-in-charge of the Food, Pharmaceutical & Alcohol Center conducted face-to-face communications at the project site for many times, from pre-sales to after-sales stages. They provided full-process guidance covering product delivery, installation, commissioning and operation. The customer expressed high recognition of our professional capabilities and service standards.            

• Lessons & Insights

The successful implementation of this project has strongly demonstrated the strategic value of efficient team collaboration. Relying on its outstanding overall planning and management capabilities, Huarong Company has built a coordinated operation mechanism covering the entire project life cycle, achieving seamless connection across departments and multiple links.

Faced with the dual challenges of customer inquiries and on-site emergencies, the team quickly formed a cohesive force to tackle key problems. It accurately identified the crux of the issues through a precise problem diagnosis system, and responded rapidly with innovative solutions that were then efficiently executed. This effort not only ensured the high-quality delivery of the project, but also established a service paradigm for multi-regional pharmaceutical projects, injecting strong impetus into the in-depth expansion of the pharmaceutical market under the group’s globalization strategy.